Polymyxins

Drug firm Aurobindo Pharma has received approval from the US health regulator to market Polymyxin B for Injection, an anti-infective drug, in the American market.

The approved product has an estimated market size of $7.6 million for the twelve months ending February 2016, according to IMS, the company said.

A gene that makes bacteria resistant to last-resort antibiotics has been found in Denmark, a new study has shown, after first being identified by researchers in China.

A new gene that makes bacteria highly resistant to a last-resort class of antibiotics has been found in people and pigs in China - including in samples of bacteria with epidemic potential, researchers said on Wednesday.

Drug firm Aurobindo Pharma has received approval from the US health regulator to market Polymyxin B for Injection, an anti-infective drug, in the American market.

The approved product has an estimated market size of $7.6 million for the twelve months ending February 2016, according to IMS, the company said.

A gene that makes bacteria resistant to last-resort antibiotics has been found in Denmark, a new study has shown, after first being identified by researchers in China.

A new gene that makes bacteria highly resistant to a last-resort class of antibiotics has been found in people and pigs in China - including in samples of bacteria with epidemic potential, researchers said on Wednesday.